Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study
NCT ID: NCT00927420
Last Updated: 2009-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2009-07-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients treated with at least one oral antipsychotic
* Subjects able to read and write
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elisa Gil
Role: STUDY_DIRECTOR
AstraZeneca Spain EpidemiologyValue Demonstration Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Las Palmas, Gran Canarias, Spain
Research Site
Calahorra, La Rioja, Spain
Research Site
Langreo, Principality of Asturias, Spain
Research Site
San Cristóbal de La Laguna, Tenerife, Spain
Research Site
Alicante, , Spain
Research Site
Almería, , Spain
Research Site
Badajoz, , Spain
Research Site
Barcelona, , Spain
Research Site
Córdoba, , Spain
Research Site
Elche, , Spain
Research Site
León, , Spain
Research Site
Lleida, , Spain
Research Site
Madrid, , Spain
Research Site
Málaga, , Spain
Research Site
Murcia, , Spain
Research Site
Ourense, , Spain
Research Site
Palma de Mallorca, , Spain
Research Site
Salamanca, , Spain
Research Site
Seville, , Spain
Research Site
Toledo, , Spain
Research Site
Valencia, , Spain
Research Site
Valladolid, , Spain
Research Site
Vitoria-Gasteiz, , Spain
Research Site
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NES-DUM-2009/1
Identifier Type: -
Identifier Source: org_study_id